New Serological Markers for Eosinophilic Esophagitis

T

Technical University of Munich

Status

Unknown

Conditions

Eosinophilic Esophagitis

Treatments

Drug: Fluticasone

Study type

Observational

Funder types

Other

Identifiers

NCT01624129
2011_0023

Details and patient eligibility

About

The purpose of the study is to investigate if serological parameters such as "extracellular Serum-Tryptase (ST)" and "eosinophilic cationic protein (ECP)" are useful for the diagnosis and surveillance of the eosinophilic esophagitis (EE).

Full description

The eosinophilic esophagitis (EE) is chronic inflammatory and immunological disease. The diagnosis of EE is based upon large numbers of eosinophils in the esophagus on histopathologic examination (> 20 eosinophils per high powered field in at least one specimen) despite acid suppression with a Proton-Pump-Inhibitor (PPI) for at least two weeks. There are no diagnostic serological markers for EE so far, so that the purpose of the study is to investigate serological markers which are established in other allergic diseases.

Enrollment

20 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • histopathological defined eosinophilic esophagitis
  • Age: 18-80

Exclusion criteria

  • missing consent form
  • contraindications for performing esophagogastroscopy/taking biopsies of the esophagus

Trial design

20 participants in 1 patient group

eosinophilic esophagitis
Description:
patients with histopathological defined eosinophilic esophagitis
Treatment:
Drug: Fluticasone

Trial contacts and locations

0

Loading...

Central trial contact

Christoph Schlag, MD; Monther Bajbouj, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems